Exact Mass: 361.2815
Exact Mass Matches: 361.2815
Found 157 metabolites which its exact mass value is equals to given mass value 361.2815,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PHA-793887
N-Arachidonoylglycine
N-Arachidonoylglycine (NAGly) is an endogenous lipid, which is a metabolite of the endocannabinoid anandamide by oxidation and acts as an efficacious agonist at GPR18. A previous study demonstrates that NAGly triggers antinociceptive and anti-inflammatory activities. A human metabolite taken as a putative food compound of mammalian origin [HMDB]
N-Arachidonoyl Glycine
N-arachidonoyl glycine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Arachidonic acid amide of Glycine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Arachidonoyl Glycine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Arachidonoyl Glycine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules. A human metabolite taken as a putative food compound of mammalian origin [HMDB]
(+)-Butaclamol
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
N-(1-Hydroxypropan-2-yl)icosa-5,8,11,14-tetraenamide
6-(6-(3r-Hydroxy-1e,5z-undecadien-1-yl)-2-pyridinyl)-1,5s-hexanediol
(Z)-N-<2-(4-hydroxy-3-methoxyphenyl)ethyl>-3-methyldodec-2-enamide|(Z)-N-[2-(4-hydroxy-3-methoxyphenyl)ethyl]-3-methyldodec-2-enamide|3-Methoxy-(Z)-N-[2-(4-Hydroxyphenyl)-ethyl]-3-methyl-2-dodecenamide
(Z)-N-<2-(3-hydroxy-4-methoxyphenyl)ethyl>-3-methyldodec-2-enamide|(Z)-N-[2-(3-hydroxy-4-methoxyphenyl)ethyl]-3-methyldodec-2-enamide|Me ether,3-hydroxy-(Z)-N-[2-(4-Hydroxyphenyl)-ethyl]-3-methyl-2-dodecenamide
Delta16-20alpha- dimethylamino-3beta,4alpha-diol-5alpha-pregnane
3beta-(dimethylamino)-pregn-16-one-20-ol|terminamine J
N-methyl N-(2-hydroxy-ethyl)arachidonoylamide
N-(5Z,8Z,11Z,14Z-heneicosatetraenoyl)-ethanolamine
5,8,11,14-all-cis-heneicosatetraenoylethanolamine
Butaclamol
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-propyl-
3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4R)- (9CI)
1-(Piperidin-1-yl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propan-2-ol
2,3,4,5-Tetrahydro-2-isobutyl-8-methyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole
4-(Triethoxysilylpropoxy)-2,2,6,6-Tetramethylpiperidine
2-[acetyl-[3-(diethylamino)propyl]amino]-N-(2,4,6-trimethylphenyl)propanamide
Butaclamol free base
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist
D-erythro-MAPP
D-erythro-MAPP (D-e-MAPP) is a ceramidase inhibitor, with an IC50 of 1-5 μM in vitro[1].
N-(1-adamantyl)-4-[oxo(2-oxolanyl)methyl]-1-piperazinecarboxamide
(5Z,8Z,11Z,14Z)-N-(1-Methyl-2-hydroxyethyl)-5,8,11,14-icosatetrenamide
(2S)-6-amino-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-hydroxypropanoyl]amino]hexanoic acid
N-[(1R,2S)-1-hydroxy-1-phenylpropan-2-yl]tetradecanamide
1-[1-(Phenylmethyl)-4-piperidinyl]-3-(2,4,4-trimethylpentan-2-yl)thiourea
(4Z,7Z,10Z,13Z,15E,17S)-17-hydroperoxydocosa-4,7,10,13,15-pentaenoate
(7Z,10Z,13Z,15E,19Z)-17-hydroperoxydocosa-7,10,13,15,19-pentaenoate
(7Z,10Z,12E,16Z,19Z)-14-hydroperoxydocosa-7,10,12,16,19-pentaenoate
(4Z,7Z,10Z,12E,16Z)-14-hydroperoxydocosa-4,7,10,12,16-pentaenoate
(8E,10Z,14E,16Z,19Z)-7,13-dihydroxydocosa-8,10,14,16,19-pentaenoate
2-[[(5E,8E,11E,14E)-Icosa-5,8,11,14-tetraenoyl]amino]acetic acid
N-[[(2R,3S,4R)-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)-N-propan-2-ylacetamide
N-[[(2S,3R,4S)-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)-N-propan-2-ylacetamide
(7Z,9E,11E,14S,16Z,19Z)-13,14-dihydroxydocosa-7,9,11,16,19-pentaenoate
(7Z,10Z,12E,14S,16Z,19Z)-14,21-dihydroxydocosa-7,10,12,16,19-pentaenoate
(7R,8E,10E,12Z,14S,16Z,19Z)-7,14-dihydroxydocosa-8,10,12,16,19-pentaenoate
7,17-dihydroxy-(8Z,15E,19Z)-docosa-8,10,13,15,19-pentaenoate
A docosanoid anion that is the conjugate base of 7,17-dihydroxy-(8Z,15E,19Z)-docosa-8,10,13,15,19-pentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(7Z,10R,11E,13E,15Z,17S,19Z)-10,17-dihydroxydocosa-7,11,13,15,19-pentaenoate
(7Z,10Z,12E,14E,17S,19Z)-16,17-dihydroxydocosa-7,10,12,14,19-pentaenoate
(7Z,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosa-7,10,12,16,19-pentaenoate
(7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosa-7,10,13,15,19-pentaenoate
resolvin T4(1-)
A docosanoid anion that is the conjugate base of resolvin T4, obtained by deprotonation of the carboxy group; major species at pH 7.3.
14(S),21-dihydroxy-(7Z,10Z,12E,16Z,19Z)-docosapentaenoate
A docosanoid anion that is the conjugate base of 14(S),21-dihydroxy-(7Z,10Z,12E,16Z,19Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(7R,14S)-dihydroxy-(8E,10E,12Z,16Z,19Z)-docosapentaenoate
A docosanoid anion that is the conjugate base of (7R,14S)-dihydroxy-(8E,10E,12Z,16Z,19Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(10R,17S)-dihydroxy-(7Z,11E,13E,15Z,19Z)-docosapentaenoate
A docosanoid anion that is the conjugate base of (10R,17S)-dihydroxy-(7Z,11E,13E,15Z,19Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
16,17(S)-dihydroxy-(7Z,10Z,13E,14E,19Z)-docosapentaenoate
A docosanoid anion that is the conjugate base of 16,17(S)-dihydroxy-(7Z,10Z,13E,14E,19Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(7Z,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosapentaenoate
A (7Z,10Z,12E,16Z,19Z)-14-hydroperoxydocosapentaenoate in which the chiral centre at position 14 has S-configuration.
(7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosapentaenoate
A (7Z,10Z,13Z,15E,19Z)-17-hydroperoxydocosapentaenoate in which the chiral centre at position 17 has S-configuration. An intermediate of specialised proresolving mediators.
13,14(S)-dihydroxy-(7Z,9E,11E,16Z,19Z)-docosapentaenoate
A docosanoid anion that is the conjugate base of 13,14(S)-dihydroxy-(7Z,9E,11E,16Z,19Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
2-amino-1,3,4,5-icosanetetrol
A tetrol that is 2-aminoicosane with the four hydroxy substituents located at position 1, 3, 4 and 5.
(13s)-13-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,13-dihydroxytridecan-4-one
(1r,2r,4r,5r,6s,7r,8r,9r,10r,13r,16s,17r)-11-ethyl-6,13-dimethyl-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,7,16-triol
4-{6-hydroxy-14-isopropyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹²]hexadecan-2-yl}butanoic acid
13-(2-hydroxyethyl)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecane-6,8-diol
(1s,2r,3r,4s,5s,8s,9s,10r,13r,16r,17r)-11-ethyl-16-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8-diol
13-[3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,13-dihydroxytridecan-4-one
n-[3-(acetyloxy)octadeca-6,9,12,15-tetraen-2-yl]ethanimidic acid
17-hydroxyhomodaphniphyllicacid
{"Ingredient_id": "HBIN002057","Ingredient_name": "17-hydroxyhomodaphniphyllicacid","Alias": "NA","Ingredient_formula": "C22H35NO3","Ingredient_Smile": "CC(C)C1CCC2(C3CCC45C(C2(C1N4C3)CCC(=O)O)CCC5O)C","Ingredient_weight": "361.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10165","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "11152646","DrugBank_id": "NA"}
